Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.36 |
| ▸ | CNR1 | P21554 | 14/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22778695 | 0.87 | ESR1 (0.34) | — | |
| SCHEMBL22752628 | 0.84 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL24967802 | 0.83 | ESR1 (0.32) | — | |
| SCHEMBL19251179 | 0.82 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL22752349 | 0.82 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL18935597 | 0.81 | CNR2 (0.34) | CNR2CNR1TLR8 | |
| SCHEMBL18431775 | 0.81 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL22752552 | 0.80 | ESR1 (0.36) | — | |
| SCHEMBL22752538 | 0.79 | NUDT1 (0.33) | CNR2CNR1TLR8 | |
| SCHEMBL22778685 | 0.79 | ESR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | CNR2 4387/4885CNR1 4057/4885TLR8 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.